# Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer

> **NCT05084677** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 96 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **COMBINATION_PRODUCT:** Toripalimab Combined With Concurrent Platinum-based Chemoradiotherapy

## Key facts

- **NCT ID:** NCT05084677
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2024-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05084677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05084677, "Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05084677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*